On a consolidated basis for the first quarter of the fiscal year ending June 2027, operating revenue was 227.917 million yen, operating loss was 61.914 million yen, ordinary loss was 61.047 million yen, and quarterly net loss was 203.339 million yen. An impairment loss of 141.341 million yen was recorded as an extraordinary loss. Full-year forecast still projects 68.7% revenue growth, but operating losses are expected to continue.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4263","jir_company_name":"SUSMED,Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4263-20261106-02.pdf","jir_short_summary":"On a consolidated basis for the first quarter of the fiscal year ending June 2027, operating revenue was 227.917 million yen, operating loss was 61.914 million yen, ordinary loss was 61.047 million yen, and quarterly net loss was 203.339 million yen. An impairment loss of 141.341 million yen was recorded as an extraordinary loss. Full-year forecast still projects 68.7% revenue growth, but operating losses are expected to continue.","jir_summary":"### Overview of Results\nSegment revenue from the DTx business and the DTx platform business totaled 227.917 million yen for the first quarter cumulative period (including 26,963 thousand yen from the DTx platform business and 200,954 thousand yen from the DTx product business). On a company-wide basis, operating loss was 61,914 thousand yen, ordinary loss was 61,047 thousand yen, and quarterly net loss was 203,339 thousand yen, with an impairment loss of 141,341 thousand yen recorded as an extraordinary loss. Milestone revenue of 200 million yen was received in connection with the termination of the sales collaboration for an insomnia app that had been covered by insurance. The company intends to continue prioritizing research and development progress while aiming to maximize long-term profitability.\n\n### Outlook and Capital\/Financial Trends\nThe full-year earnings forecast remains unchanged from the previously announced guidance, with revenue expected to increase 68.7% year-over-year. However, an operating loss is still forecast, and the recording of extraordinary losses including impairment could affect the financial position. Assets stood at 4,021,750 thousand yen in current assets, 166,990 thousand yen in non-current assets, and 3,886,815 thousand yen in net assets. The number of stock acquisition rights has increased, which may affect shareholder composition.","jir_financial_highlights":"Operating Revenue: 227,917 thousand yen (Year-over-Year Unknown (Prior comparable period: 45,868 thousand yen))\nOperating Loss: -61,914 thousand yen (Prior comparable period: -133,043 thousand yen)\nOrdinary Loss: -61,047 thousand yen (Prior comparable period: -132,954 thousand yen)\nQuarterly Net Loss: -203,339 thousand yen (Prior comparable period: -120,657 thousand yen)\nImpairment Loss (Extraordinary Loss): 141,341 thousand yen (Prior comparable period: 0)\nAsset Retirement Obligations: 95,367 thousand yen (Increase from fiscal year-end)","jir_category":"","jir_hashtags":"#SUSMED, #Earnings, #DTx, #MedicalSoftware, #Impairment","jir_key_figures":"Operating Revenue 227,917 thousand yen (First quarter cumulative)\nOperating Loss -61,914 thousand yen\nQuarterly Net Loss -203,339 thousand yen\nImpairment Loss 141,341 thousand yen\nEquity Ratio 90.2% (First quarter)","jir_meta_title":"SUSMED,Inc. Q1 Financial Summary for FY ending June 2027 | Revenue Growth Outlook Amid Expanding Losses","jir_meta_description":"Key points from SUSMED,Inc.'s Q1 financial summary for the fiscal year ending June 2027: segment revenues, profit and loss, impairment trends, and outlook. Review the impact of milestone income and developments in the DTx platform business.","jir_og_title":"SUSMED,Inc. Releases Q1 Financial Results | Revenue and Profit Trends","jir_og_description":"Performance and financial trends for the first quarter centered on the DTx business, including impairment recognition and outlook.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend (Quarterly Cumulative)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 2026\\\",\\\"Q2 2026\\\",\\\"Q3 2026\\\",\\\"Q4 2026\\\",\\\"Q1 2027\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Revenue\\\",\\\"data\\\":[45868,0,0,0,227917]},{\\\"label\\\":\\\"Inter-segment\/External Revenue\\\",\\\"data\\\":[45868,227917,0,0,0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 2026\\\",\\\"Q2 2026\\\",\\\"Q3 2026\\\",\\\"Q4 2026\\\",\\\"Q1 2027\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Profit\\\",\\\"data\\\":[-133043,0,0,0,-61914]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"DTx Product\\\",\\\"DTx Platform\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Revenue\\\",\\\"data\\\":[200954,26963]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 2026\\\",\\\"Q1 2027\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Profit Margin\\\",\\\"data\\\":[-0., -0.0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Comparison of Guidance and Results\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Full Year 2027\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Full-year Forecast Revenue\\\",\\\"data\\\":[838]},{\\\"label\\\":\\\"Full-year Forecast Net Income\\\",\\\"data\\\":[-32.09]}]},\\\"options\\\":{}}\"}]","ir_related_company":58337,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-144025","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n